Statin and beta-blocker therapy and the initial presentation of coronary heart disease
Alan S Go1, Carlos Iribarren, Malini Chandra
1Division of Research, Kaiser Permanente of Northern California, Oakland, California 94612-2304, USA. Alan.S.Go@kp.org
Annals of Internal Medicine
|February 24, 2006
Summary
Statin and beta-blocker use was linked to fewer acute myocardial infarction (heart attack) cases compared to stable angina. These findings suggest potential protective effects against severe coronary disease presentations.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Background:
- Coronary atherosclerosis is a chronic condition often presenting as sudden, unstable events like acute myocardial infarction (AMI).
- Patients with AMI may differ significantly from those with stable exertional angina.
Purpose of the Study:
- To investigate if patient characteristics or medication use influence the initial clinical presentation of coronary artery disease.
- To compare factors associated with acute myocardial infarction versus stable exertional angina.
Main Methods:
- A case-control study was conducted within a large healthcare system.
- Included adults with initial presentations of either AMI (n=916) or stable exertional angina (n=468).
- Data on cardiac medication use, demographics, lifestyle, and clinical factors were collected.
Main Results:
- Patients with AMI were more likely to be male, smokers, inactive, and hypertensive, but less likely to have a family history of coronary disease.
- AMI patients were significantly less likely to have used statins (19.3%) or beta-blockers (19.0%) compared to exertional angina patients (40.4% and 47.7%, respectively).
- Statin and beta-blocker use were associated with reduced odds of presenting with AMI versus stable angina.
Conclusions:
- Statin and beta-blocker use correlated with a lower likelihood of experiencing an acute myocardial infarction as the initial presentation.
- Further research is required to confirm the protective role of these medications against severe coronary disease events.
- Limitations include potential unmeasured confounding factors, such as aspirin use.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...